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Abstract The activity of ADAMTS13, the von Willebrand
factor cleaving protease, is deficient in patients with
thrombotic thrombocytopenic purpura (TTP). In the present
study, the phenotype of ADAMTS13 in TTP and in normal
plasma was demonstrated by immunoblotting. Normal
plasma (n=20) revealed a single band at 190 kD under
reducing conditions using a polyclonal antibody, and a
single band at 150 kD under non-reducing conditions using
a monoclonal antibody. ADAMTS13 was not detected in
the plasma from patients with congenital TTP (n=5) by
either antibody, whereas patients with acquired TTP (n=2)
presented the normal phenotype. Following immunoadsorp-
tion of immunoglobulins, the ADAMTS13 band was
removed from the plasma of the patients with acquired
TTP, but not from that of normal individuals. This indicates
that ADAMTS13 is complexed with immunoglobulin in
these patients. The lack of ADAMTS13 expression in the
plasma from patients with hereditary TTP may indicate
defective synthesis, impaired cellular secretion, or enhanced
degradation in the circulation. This study differentiated
between normal and TTP plasma, as well as between
congenital and acquired TTP. This method may, therefore,
be used as a complement in the diagnosis of TTP.
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Introduction
Von Willebrand factor (VWF) is a glycoprotein that plays a
key role in the primary hemostatic process by inducing
platelet adhesion and aggregation at sites of vascular injury
under conditions of high shear stress. The main source of
circulating VWF is the endothelium, from which it is secreted
in the form of ultra-large multimers (ULVWF) [53]. ULVWF
multimers are biologically very active [2, 31]a n d ,u p o n
release, undergo processing into smaller multimers in normal
individuals. This occurs on the surface of endothelial cells
[10]. VWF defects may potentially lead to both bleeding and
thrombotic disorders: defective VWF secretion, intravascular
clearance, multimer assembly, or increased proteolytic
degradation may lead to different types of von Willebrand
disease. On the other hand, dysfunctional VWF proteolysis
may lead to the thrombotic disorder thrombotic thrombocy-
topenic purpura (TTP) [40].
TTP is a thrombotic microangiopathy (TMA) character-
ized by microangiopathic hemolytic anemia, thrombocyto-
penia, fever, neurological and renal manifestations. Chronic
recurrent TTP has been associated with the presence of
ULVWF in the plasma [30]. ULVWF multimers are capable
of inducing increased platelet retention in children with
TTP [21]. These observations, along with the finding of
VWF and platelet-rich (but fibrin-poor) thrombi in the
microcirculation of the heart, brain, kidneys, liver, spleen,
and adrenals in TTP patients [3], led to the conclusion that
ULVWF multimers are responsible for the disseminated
platelet thrombi occurring in TTP and that their degradation
to smaller VWF multimers is impaired due to the deficiency
of a VWF-cleaving protease [15].
Recently, the VWF-cleaving protease was purified [12,
13, 16, 50] and the encoding gene sequenced, linking the
protease to the ADAMTS (a disintegrin-like and metal-
loprotease with thrombospondin-type-1 motif) family of
metalloproteases [27]. The protease, named ADAMTS13,
cleaves VWF at the 1605Tyr-1606Met peptide bond in the
A2 domain, yielding the 140-kD and 176-kD VWF frag-
ments present in normal plasma [13, 50]. Cleavage is made
possible by a conformational change in VWF due to shear
stress in the circulation, which exposes the cleavage site,
making it susceptible to proteolysis [55]. ADAMTS13
activity is severely deficient (<5% of normal plasma
activity) in TTP patients [6], either due to a mutation in
the ADAMTS13 gene in the congenital form of TTP or due
to auto-antibodies in the acquired form [14, 27, 52].
Autosomal recessive hereditary TTP (also termed the
Upshaw-Schulman syndrome) typically presents during
the neonatal period or early childhood (<10 years of age),
but may also manifest during adolescence and adulthood.
Recurrent TTP episodes may occur as often as every third
week. TTP recurrences are associated with cerebral vascu-
lar accidents in approximately 30% of cases, and these
episodes may lead to neurological complications. Renal
manifestations may be mild or may result in acute renal
failure due to hemoglobinuria and TMA. About 20% of
patients progress to end-stage renal failure [28].
Hemolytic uremic syndrome (HUS) is a similar micro-
angiopathic disorder characterized by microangiopathic
hemolytic anemia, thrombocytopenia, and acute renal
failure [5]. Two forms of HUS have been described: D+
or typical (diarrhea-associated) HUS and D- or atypical
(non-diarrhea-associated) HUS. D+ HUS occurs after
infection with Shiga-like toxin producing bacteria, typical-
ly, enterohemorrhagic Escherichia coli. The patients are
usually children presenting with abrupt onset of diarrhea,
followed by the development of HUS 2–10 days later. A
prothrombotic state precedes the acute renal failure [8], but
the pathogenetic mechanism is, as yet, unclear. It is
assumed that bacterial virulence factors gain access to the
circulation, circulate on blood cells, activate platelets, and
reach the kidney, where the endothelium is injured [36, 47].
D- HUS is associated with mutations in certain complement
regulatory factors, such as factor H, factor I, and membrane
co-factor protein (CD46). The mutations lead to activation
of the complement system on host endothelial cells [29,
58]. The resulting vascular damage may lead to the
formation of thrombotic lesions in the kidneys.
Although HUS patients are, typically, young children
with a history of diarrhea and acute renal failure, the
clinical manifestations of HUS and TTP often overlap,
making differentiation between the two syndromes based
solely on clinical presentation difficult. ADAMTS13
antigen levels can differentiate between HUS and TTP, as
they are severely deficient in patients with congenital TTP
and normal to moderately reduced in HUS [51]. Assays for
ADAMTS13 activity can, therefore, differentiate between
TTP (congenital and acquired) and HUS [26, 48].
Several ADAMTS13 assays are available today based on
antigen detection and activity [15, 17, 25, 38], showing the
presence of the protease (by enzyme-linked immunosorbent
assay, ELISA) and its bioactivity in normal plasma and the
lack of protease and activity in the plasma from patients
with congenital TTP. These assays have also shown that
patients with acquired TTP have auto-antibodies that
neutralize the activity of ADAMTS13. The present study
utilized a different method, immunoblotting, and two anti-
ADAMTS13 antibodies against specific domains, to inves-
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plasma, TTP plasma (congenital and acquired), and in
heterozygous carriers of ADAMTS13 mutations, demon-
strating the presence of ADAMTS13 and its size in normal
plasma, the lack thereof in congenital TTP, and auto-
antibody-bound protease in acquired TTP.
Materials and methods
Subjects
Citrated plasma was available from patients with congenital
(n=5) and acquired (n=2) TTP. The patient data are
presented in Table 1. The ADAMTS13 activity level was
assayed as previously described [15, 17].
The study also included the parents of patients 1–4. The
parents of patients 1 and 2 are both heterozygous for the
4143insA mutation, and have protease activity levels of
20% (mother) and 50% (father), as assayed by the VWF
multimeric structure analysis [15]. The parents of patient 3
are heterozygous for the P353L (mother) and P457L
(father) mutations, and both have 50% ADAMTS13
activity. The parents of patient 4 are heterozygous for
P671L (mother) and 4143insA (father), and have 50%
ADAMTS13 activity. All parents are clinically unaffected.
Plasma samples from 20 healthy adult volunteers were
used as controls. The study was conducted with the
approval of the ethics committee of Lund University and
the plasma samples were collected with the informed
consent of the patients, their parents, and the controls.
Table 1 Clinical and laboratory data regarding thrombotic thrombocytopenic purpura (TTP) patients
Patient
no.
Sex Age
at
debut
Age at
sampling
(years)
Current
age
(years)
Symptoms during episodes No. of
episodes
ADAMTS13
activity level
ADAMTS13
mutation
ADAMTS13
inhibitor
Reference
1
a M 2 d 16 19 Jaundice, hemolytic anemia,
thrombocytopenia, macroscopic
hematuria, pathological urinalysis,
fever, neurological symptoms,
elevated serum creatinine
>5 <5% 4143insA
bc None [4, 20, 43]
2
a M 5.3 y 17 18 Jaundice, hemolytic anemia,
thrombocytopenia, fever,
neurological symptoms,
pathological urinalysis
>5 <5% 4143insA
bc None [4, 20, 43]
3 F 20 m 15 23 Hemolytic anemia,
thrombocytopenia, hematuria,
epileptic attacks, slightly elevated
serum creatinine
>5 <5% P353L
d,
P457L
e
None [4]
4 M 3 y 7 9 Hemolytic anemia,
thrombocytopenia, purpura,
pathological urinalysis
4 <5% P671L
f,
4143insA
None [43]
5 M 2 d 39 39 Jaundice, hemolytic anemia,
petechiae, thrombocytopenia,
transitory neurological deficits and
aphasia, elevated creatinine
>5 <5% 4143insA
b None –
6 F 54 y 70 75 Recurrent hemolytic anemia and
thrombocytopenia, reduced
consciousness, pathological
urinalysis
>5 <5% NA 0.5 U/ml –
7 F 25 y 42 44 Thrombocytopenia, hemolytic
anemia, elevated creatinine during
viral infection and pregnancy
2 <5% NA 0.2 U/ml –
aPatients 1 and 2 are siblings
bPatients 1, 2, and 5 are homozygous for the ADAMTS13 mutation
c4143insA leads to a mutation in the second CUB domain
dP353L is a mutation in the disintegrin-like domain
eP457L is a mutation in the cysteine-rich domain
fP671L is a mutation in the spacer domain
NA: not assayed
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At the time of sampling, the patients were treated regularly
with fresh frozen plasma or Octaplas (Octapharma, Stock-
holm, Sweden; patients 1–5). Patient 6 was treated with
plasma infusions every sixth week. Patient 7 did not receive
any plasma treatment at sampling. All blood samples were
obtained at least three weeks (patients 1–4 and 6) or one
week (patient 5) after the last treatment. Venous blood from
patients and controls was collected, and the plasma
obtained as previously described [20].
Anti-ADAMTS13 antibodies
A polyclonal anti-peptide antibody was raised in New
Zealand white rabbits against a unique sequence in the
second CUB domain (AA1413-1427) and affinity-purified
against the peptide. Antibody specificity was tested by
ELISA (plates coated with the peptide) and by immunoblot-
ting with purified plasma ADAMTS13 [50] under reducing
(SDS-PAGE) and non-reducing (dot blot) conditions.
The monoclonal antibody A10 [56], directed against the
disintegrin-like domain, was used to confirm the results of
the polyclonal antibody. The polyclonal antibody reacted
with ADAMTS13 under reducing (reduced by the addition
of 2-mercaptoethanol to disrupt disulfide bonds in the
protease) and non-reducing conditions, whereas the mono-
clonal antibody reacted with ADAMTS13 only under non-
reducing conditions.
Immunoblot analysis for the detection of ADAMTS13
in plasma
The plasma samples (1:20) were subject to SDS-PAGE
under reducing (for blotting with the polyclonal antibody)
and non-reducing conditions (for blotting with the mono-
clonal antibody) [19, 58]. Purified plasma ADAMTS13
(1:100) was used as the control for the polyclonal antibody.
Immunoblotting was performed with rabbit anti-
ADAMTS13 IgG 1.6 μg/ml followed by goat anti-rabbit
IgG HRP (DakoCytomation, Carpinteria, CA) 1:2000, or
with mouse anti-ADAMTS13 IgG 0.6 μg/ml followed by
goat anti-mouse IgG HRP (DakoCytomation, Carpinteria,
CA) 1:2000. The signal was detected by chemilumines-
cence. The specificity of the signal obtained with the
polyclonal antibody was tested by preincubation with a 50-
fold molar surplus of blocking peptide followed by
immunoblotting with the blocked antibody. The specificity
of the secondary antibodies was tested by omission of the
primary antibodies.
Immunoblotting with the polyclonal antibody revealed, in
addition to ADAMTS13, two unspecific bands at 130 kD and
170 kD, which were identified as C3 and alpha-2-macroglob-
ulin. These proteins were removed by incubating the plasma
samples with protein A-sepharose coupled rabbit anti-C3 IgG
and rabbit anti-alpha-2-macroglobulin IgG. The results
obtained using the polyclonal antibody show samples from
which these proteins have been removed.
In order to investigate the presence of ADAMTS13-
autoantibody complexes in the plasma from patients with
acquired TTP, samples were passed onto protein G-
sepharose (Amersham Biosciences, Buckinghamshire,
UK) prior to immunoblotting. Normal plasma (n=2) was
used for comparison.
Results
Detection of ADAMTS13 in plasma samples from normal
individuals
Normal plasma under reducing conditions revealed a single
immunoreactive band at 190 kD when blotted against the
polyclonal antibody (Fig. 1a). Purified plasma ADAMTS13
showed a similar band under the same conditions (Fig. 1a).
The monoclonal antibody detected an immunoreactive band
at 150 kD in normal plasma under non-reducing conditions
(Fig. 1b). Preincubation of the polyclonal antibody with the
blocking peptide abolished the ADAMTS13 band in
normal plasma (data not shown). Immunoblots in which
the primary antibodies had been omitted showed no bands
(data not shown).
Detection of ADAMTS13 in plasma samples from TTP
patients
The plasma samples from all patients with congenital TTP,
regardless of the mutation, lacked the ADAMTS13 band
(Fig. 1c). Patients 6 and 7 with acquired TTP revealed the
same ADAMTS13 protein expression pattern as the
controls (Fig. 1c). These results were obtained using both
the polyclonal (Fig. 1c) and the monoclonal antibody
(Fig. 1d). When immunoadsorption of plasma immuno-
globulins was carried out prior to immunoblotting, the
ADAMTS13 band remained visible in normal plasma, but
was completely removed from the samples of the patients
with acquired TTP (Fig. 1e), probably due to its association
with the immunoglobulin inhibitor.
Detection of ADAMTS13 in the parents of the TTP patients
The parents of the TTP patients are all carriers of one
ADAMTS13 mutation and one normal allele. All parents
presented a normal ADAMTS13 phenotype using both the
polyclonal (data not shown) and the monoclonal antibody
(Fig. 1g).
252 Eur J Pediatr (2007) 166:249–257Discussion
In the present study, we detected ADAMTS13 in plasma
using a polyclonal and a monoclonal antibody. This assay
was capable of distinguishing TTP patients from normal
individuals, as well as differentiating between congenital
and acquired TTP. Plasma from the patients with congenital
TTP lacked the ADAMTS13 antigen. In contrast, the
plasma of patients with acquired TTP expressed a normal
ADAMTS13 phenotype.
Previous studies describing the ADAMTS13 phenotype
in normal plasma by immunoblotting with other specific
anti-ADAMTS13 antibodies have shown immunoreactive
bands of the same molecular weight using similar con-
ditions [33, 46]. The ADAMTS13 antigen in patients with
congenital and acquired TTP has recently been shown by
ELISA, demonstrating low to undetectable ADAMTS13
levels in patients with congenital TTP [11, 38]a n d
decreased, but mostly detectable, levels in patients with
acquired TTP [11, 38, 45]. In the present study, the
ADAMTS13 phenotype in TTP patients is described by
immunoblotting, confirming the lack of ADAMTS13
antigen in the plasma of patients with congenital TTP and
the presence of circulating complexes in acquired TTP.
Furthermore, we showed that heterozygous carriers of the
ADAMTS13-related mutations who, thus, have reduced
ADAMTS13 bioactivity have a normal phenotype.
The plasma of the patients with congenital TTP did not
present the ADAMTS13 band. This may be due to altered
synthesis, secretion or antigenicity, or due to increased
breakdown of the protease in plasma. The fact that two
antibodies directed to two different domains in
ADAMTS13 were unable to detect the protease band
makes altered antigenicity less likely to be the cause for
the lack of the ADAMTS13 band in these patients.
Previous studies have shown impaired secretion of the
4143insA (patients 1, 2, 4, and 5) [35, 42, 44] and P353L
(patient 3) [42] mutants from cells, thus, indicating that the
protease may accumulate intracellularly, at least in some
patients with congenital TTP. This may be due to a missing
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R Fig. 1a–g Detection of ADAMTS13 in normal and thrombotic
thrombocytopenic purpura (TTP) plasma. a The polyclonal antibody
detected a single band at 190 kD in normal plasma (NP) under
reducing conditions. Purified plasma ADAMTS13 in the right lane
showed a similar band. b Normal plasma under non-reducing
conditions revealed an immunoreactive band at 150 kD when blotted
against the monoclonal antibody. c Immunoblotting with the poly-
clonal antibody revealed that patients 1–5 with congenital TTP all
lacked the ADAMTS13 band, whereas patients 6 and 7 with acquired
TTP presented a normal expression pattern. Normal plasma (NP) was
run on the same gel for comparison. d These results were confirmed
by the monoclonal anti-ADAMTS13 antibody. e Immunoblot using
the polyclonal antibody. Immunoadsorption of immunoglobulins from
the plasma samples of patients 6 and 7 with acquired TTP lead to the
simultaneous removal of the ADAMTS13 band, indicating that
ADAMTS13 is complexed with the anti-ADAMTS13 auto-antibodies.
In contrast, the ADAMTS13 band remained visible in normal plasma
(NP) treated similarly. f A schematic presentation of the mechanism
by which the removal of immunoglobulins leads to the removal of the
ADAMTS13 antigen from the plasma of patients with acquired TTP.
The plasma sample contains ADAMTS13 ( filled circles), auto-
antibodies to ADAMTS13 (⤙), and various other plasma proteins
(open circles). Immunoblotting of the plasma sample prior to the
removal of immunoglobulins detects the presence of ADAMTS13
antigen. Passage of the plasma sample through a protein G-sepharose
column leads to the binding and removal of all immunoglobulins from
the sample. Since ADAMTS13 is bound to the anti-ADAMTS13
auto-antibodies, it is removed along with them. Immunoblotting of the
flow-through shows no ADAMTS13 band. g Immunoblot with the
monoclonal antibody showing a normal ADAMTS13 band in the
plasma of the parents, which are all heterozygous for one mutated
allele and are clinically unaffected. Lane 1: the mother of patients 1
and 2, 4143insA; lane 2: the mother of patient 3, P353L; lane 3: the
father of patient 3, P457L; lane 4: the mother of patient 4, P671L; lane
5: the father of patient 4, 4143insA. Normal plasma (NP) was run on
the same gel for comparison
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conformational changes in the protein, impairing its
secretion. Similar findings regarding two other
ADAMTS13 mutations, V88M and G239V, have been
recently reported [34]. A total lack of ADAMTS13 activity
in the plasma is thought to be incompatible with life [27],
thus, the patients may have very low amounts of
ADAMTS13 activity in their plasma, which we were
unable to detect with this method.
The patients with acquired TTP presented with a normal
ADAMTS13 band, which is consistent with the fact that
ADAMTS13 protease genotype and expression are normal,
but their activity is lower, due auto-antibodies [11, 14, 41,
45, 52]. The finding that the immunoadsorption of immuno-
globulins from the plasma of the patients with acquired TTP
also led to the removal of the ADAMTS13 antigen from
their samples indicates that the protease is complexed with
the auto-antibodies in the circulation of these patients, and
that this occurs even during clinical remission.
The majority of the ADAMTS13 assays available today
detectADAMTS13activitylevelsinplasma(Table2). This is
performed either by detecting the VWF products resulting
from ADAMTS13 cleavage (assays 1–5) or by measuring
the residual VWF activity (assays 6–7). The VWF substrate
utilized in these assays may be high molecular weight VWF
(plasma-derived or recombinant; assays 1–4) or VWF
domains or short synthetic peptides (assay 5). Two multi-
center studies evaluating methods 1, 3–5, and 6–7s h o w e d
that all assays were able to detect severely ADAMTS13-
deficient plasma samples and indicated that methods 1, 6,
and 7 were the most consistent and reliable methods
[48, 49]. A recent smaller study evaluating the FRETS-
VWF73 method (assay 5) showed that this is a reliable assay
which provides results in good accordance with other
methods [26].
Few recent studies have shown that ADAMTS13 antigen
was detectable in plasma by ELISA (assay 8 in Table 2).
ELISA assays are a valuable complement to the
ADAMTS13 activity assays, and offer a fast analysis of
the ADAMTS13 antigen levels in plasma samples using
antibodies directed to ADAMTS13. These assays are able
to distinguish ADAMTS13-deficient TTP plasma from
normal plasma samples. Other methods are capable of
detecting anti-ADAMTS13 auto-antibodies (Table 2, assays
8–9). Mutational analysis can be carried out by polymerase
chain reaction (PCR) in order to detect mutations in the
ADAMTS13 gene (assay 11 in Table 2).
In the present study, we developed a qualitative, semi-
quantitative assay capable of detecting ADAMTS13 anti-
gen and anti-ADAMTS13 auto-antibodies in plasma and,
Table 2 ADAMTS13 assays
ASSAY PRINCIPLE REFERENCE
Detection of ADAMTS13 activity
Detection of VWF cleavage products
1. VWF multimer structure analysis Detection of the breakdown of high-molecular-weight VWF [15, 23]
2. Immunoblotting of VWF Detection of cleavage products of native VWF or
recombinant VWF domains
[37, 50]
3. IRMA Detection of VWF cleavage products [32]
4. Flow assay Detection of the breakdown of ULVWF-platelet strings
attached to endothelial cells
[1]
5. Various methods using VWF domains or short synthetic VWF
peptides as the substrate, such as the FRETS-VWF73 assay
Detection of cleavage products of the VWF domains or VWF
peptides
[9, 18, 22,
25, 59–61]
Detection of VWF residual activity
6. Collagen binding Detection of VWF binding to collagen; binding correlates
to VWF multimer size
[17]
7. Ristocetin cofactor activity Detection of platelet aggregates; VWF ability to induce
platelet aggregates in the presence of ristocetin correlates
to multimer size
[7]
Detection of ADAMTS13 antigen and auto-antibodies
8. ELISA Detection of ADAMTS13 antigen or anti-ADAMTS13
auto-antibodies
[11, 38, 39,
41, 54]
9. Immunoblotting Detection of anti-ADAMTS13 auto-antibodies [57]
10. Present assay (immunoblotting) Detection of ADAMTS13 antigen and size and (indirectly)
of auto-antibodies
–
Mutation analysis
11. PCR Detection of mutations in the ADAMTS13 gene [27]
IRMA: immunoradiometric assay; FRET: fluorescence resonance energy transfer; FRETS-VWF73: a 73-amino-acid-long synthetic peptide which
provides a minimal substrate for ADAMTS13 [24] that has been made fluorogenic; PCR: polymerase chain reaction
254 Eur J Pediatr (2007) 166:249–257thus, distinguishing between TTP and normal plasma, as
well as distinguishing between congenital and acquired
TTP. All patients with congenital TTP, regardless of their
ADAMTS13 mutations, presented with undetectable levels
of ADAMTS13 antigen, whereas patients with acquired
TTP presented a normal phenotype. Heterozygous carriers
of ADAMTS13 mutations also revealed a normal
ADAMTS13 antigen band. Although not a quantitative
method like the above-mentioned ELISA assays, the
present assay offers the advantage of not only demonstrat-
ing the presence or absence of ADAMTS13 antigen, but
also the molecular size of ADAMTS13 present in plasma
samples. Furthermore, this assay was able to show the
presence of anti-ADAMTS13 antibodies indirectly by
performing immunoadsorption of plasma immunoglobulins
prior to immunoblotting. In conclusion, this assay is able to
distinguish between normal and TTP plasma, and also
between congenital and acquired TTP. It is easy to perform
and can be used at any hospital laboratory routinely using
SDS-PAGE electrophoresis and immunoblotting, and offers
a complement to existing ADAMTS13 methods in the
diagnosis of TTP.
Acknowledgments The authors thank Professor M. Furlan, Central
Hematology Laboratory, Inselspital, University of Bern, Switzerland,
for initially performing the ADAMTS13 protease activity assays on
patients 1, 2, and 3. We also thank Drs. Y. Fujimura and H. Hiura for
providing us with their monoclonal (A10) mouse anti-ADAMTS13
antibody.
References
1. Amar S, Rice L, Dong J-F, Chow T, Nolasco L, Bernardo A,
Baker KR, Moake JL (2002) Evaluation of ADAMTS-13 von
Willebrand factor-cleaving metalloprotease activity using a rapid
endothelial cell surface-based assay in two chronic relapsing TTP
patients receiving plasma infusion. Blood 100:684a
2. Arya M, Anvari B, Romo GM, Cruz MA, Dong J-F, McIntire LV,
Moake JL, Lopez JA (2002) Ultralarge multimers of von
Willebrand factor form spontaneous high-strength bonds with
the platelet glycoprotein Ib-IX complex: studies using optical
tweezers. Blood 99(11):3971–3977
3. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K
(1985) Immunohistochemistry of vascular lesion in thrombotic
thrombocytopenic purpura, with special reference to factor VIII
related antigen. Thromb Res 38(5):469–479
4. Assink K, Schiphorst R, Allford S, Karpman D, Etzioni A,
Brichard B, van de Kar N, Monnens L, van den Heuvel L (2003)
Mutation analysis and clinical implications of von Willebrand
factor-cleaving protease deficiency. Kidney Int 63(6):1995–1999
5. Besbas N, Karpman D, Landau D, Loirat C, Proesmans W,
Remuzzi G, Rizzoni G, Taylor CM, van de Kar N, Zimmerhackl
LB;European Paediatric Research Group for HUS (2006) A
classification of hemolytic uremic syndrome and thrombotic
thrombocytopenic purpura and related disorders. Kidney Int 70
(3):423–431
6. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B (2002) von
Willebrand factor-cleaving protease (ADAMTS13) in thrombocy-
topenic disorders: a severely deficient activity is specific for
thrombotic thrombocytopenic purpura. Blood 100(2):710–713
7. Böhm M, Vigh T, Scharrer I (2002) Evaluation and clinical
application of a new method for measuring activity of von
Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann
Hematol 81(8):430–435
8. Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD,
Watkins SL, Igarashi T, Tarr PI (2002) Prothrombotic coagulation
abnormalities preceding the hemolytic-uremic syndrome. N Engl J
Med 346(1):23–32
9. Cruz MA, Whitelock J, Dong J-F (2003) Evaluation of ADAMTS-
13 activity in plasma using recombinant von Willebrand Factor A2
domain polypeptide as substrate. Thromb Haemost 90(6):1204–
1209
10. Dong J-F, Moake JL, Nolasco L, Bernardo A, Arceneaux W,
Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA
(2002) ADAMTS-13 rapidly cleaves newly secreted ultralarge
von Willebrand factor multimers on the endothelial surface under
flowing conditions. Blood 100(12):4033–4039
11. FeysHB, Liu F, DongN, Pareyn I, Vauterin S, Vandeputte N, Noppe
W, Ruan C, Deckmyn H, Vanhoorelbeke K (2006) ADAMTS-13
plasma level determination uncovers antigen absence in acquired
thrombotic thrombocytopenic purpura and ethnic differences.
J Thromb Haemost 4(5):955–962
12. Fujikawa K, Suzuki H, McMullen B, Chung D (2001) Purification
of human von Willebrand factor-cleaving protease and its
identification as a new member of the metalloproteinase family.
Blood 98(6):1662–1666
13. Furlan M, Robles R, Lamie B (1996) Partial purification and
characterization of a protease from human plasma cleaving von
Willebrand factor to fragments produced by in vivo proteolysis.
Blood 87(10):4223–4234
14. Furlan M, Robles R, Solenthaler M, Lämmle B (1998) Acquired
deficiency of von Willebrand factor-cleaving protease in a patient
with thrombotic thrombocytopenic purpura. Blood 91(8):2839–
2846
15. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle
B (1997) Deficient activity of von Willebrand factor-cleaving
protease in chronic relapsing thrombotic thrombocytopenic purpura.
Blood 89(9):3097–3103
16. Gerritsen HE, Robles R, Lämmle B, Furlan M (2001) Partial
amino acid sequence of purified von Willebrand factor-cleaving
protease. Blood 98(6):1654–1661
17. Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M
(1999) Assay of von Willebrand factor (vWF)-cleaving protease
based on decreased collagen binding affinity of degraded vWF: a
tool for the diagnosis of thrombotic thrombocytopenic purpura
(TTP). Thromb Haemost 82(5):1386–1389
18. Jin M, Cataland S, Bissell M, Wu HM (2006) A rapid test for the
diagnosis of thrombotic thrombocytopenic purpura using surface
enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-
mass spectrometry. J Thromb Haemost 4(2):333–338
19. Kahn R, Herwald H, Muller-Esterl W, Schmitt R, Sjogren AC,
Truedsson L, Karpman D (2002) Contact-system activation in
children with vasculitis. Lancet 360(9332):535–541
20. Karpman D, Holmberg L, Jirgard L, Lethagen S (1996) Increased
platelet retention in familial recurrent thrombotic thrombocytopenic
purpura. Kidney Int 49(1):190–199
21. Karpman D, Lethagen S, Kristoffersson A, Isaksson C, Holmberg
L (1997) von Willebrand factor mediates increased platelet
retention in recurrent thrombotic thrombocytopenic purpura.
Thromb Haemost 78(6):1456–1462
22. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H,
Fujimura Y (2006) Novel monoclonal antibody-based enzyme
immunoassay for determining plasma levels of ADAMTS13
activity. Transfusion 46(8):1444–1452
Eur J Pediatr (2007) 166:249–257 25523. Knovich MA, Craver K, Matulis MD, Lawson H, Owen J
(2004) Simplified assay for VWF cleaving protease
(ADAMTS13) activity and inhibitor in plasma. Am J Hematol
76(3):286–290
24. Kokame K, Matsumoto M, Fujimura Y, Miyata T (2004) VWF73,
a region from D1596 to R1668 of von Willebrand factor, provides
a minimal substrate for ADAMTS-13. Blood 103(2):607–612
25. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T (2005)
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13
assay. Br J Haematol 129(1):93–100
26. Kremer Hovinga JA, Mottini M, Lämmle B (2006) Measurement
of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay:
comparison with other assay methods. J Thromb Haemost 4(5):
1146–1148
27. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee
BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R,
Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE,
Upshaw JDJr, Ginsburg D, Tsai H-M (2001) Mutationsin a member
of the ADAMTS gene family cause thrombotic thrombocytopenic
purpura. Nature 413(6855):488–494
28. Loirat C, Veyradier A, Girma JP, Ribba AS, Meyer D (2006)
Thrombotic thrombocytopenic purpura associated with von
Willebrand factor-cleaving protease (ADAMTS13) deficiency in
children. Semin Thromb Hemost 32(2):90–97
29. Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S,
Jozsi M, Neumann HP, Remuzzi G, Zipfel PF (2003) Mutations in
factor H reduce binding affinity to C3b and heparin and surface
attachment to endothelial cells in hemolytic uremic syndrome.
J Clin Invest 111(8):1181–1190
30. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM,
Azocar J, Seder RH, Hong SL, Deykin D (1982) Unusually large
plasma factor VIII:von Willebrand factor multimers in chronic
relapsing thrombotic thrombocytopenic purpura. N Engl J Med
307(23):1432–1435
31. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums
JD (1986) Involvement of large plasma von Willebrand factor
(vWF) multimers and unusually large vWF forms derived from
endothelial cells in shear stress-induced platelet aggregation.
J Clin Invest 78(6):1456–1461
32. Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP
(1999) Estimation of the von Willebrand factor-cleaving protease
in plasma using monoclonal antibodies to vWF. Thromb Haemost
82(5):1382–1385
33. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y,
Ishiwata A, Takano K, Ohmori T, Sakata Y (2006) Severe
secondary deficiency of von Willebrand factor-cleaving protease
(ADAMTS13) in patients with sepsis-induced disseminated
intravascular coagulation: its correlation with development of
renal failure. Blood 107(2):528–534
34. Peyvandi F, Lavoretano S, Palla R, Valsecchi C, Merati G, De
Cristofaro R, Rossi E, Mannuccio Mannucci P (2006) Mecha-
nisms of the interaction between two ADAMTS13 gene mutations
leading to severe deficiency of enzymatic activity. Hum Mutat
27(4):330–336
35. Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN,
Hogg PJ (2004) Congenital thrombotic thrombocytopenic purpura
in association with a mutation in the second CUB domain of
ADAMTS13. Blood 103(2):627–629
36. Proulx F, Seidman EG, Karpman D (2001) Pathogenesis of Shiga
toxin-associated hemolytic uremic syndrome. Pediatr Res 50(2):
163–171
37. Remuzzi G, Galbusera M, Noris M, Canciani MT, Daina E, Bresin
E, Contaretti S, Caprioli J, Gamba S, Ruggenenti P, Perico N,
Mannucci PM (2002) von Willebrand factor cleaving protease
(ADAMTS13) is deficient in recurrent and familial thrombotic
thrombocytopenic purpura and hemolytic uremic syndrome.
Blood 100(3):778–785
38. Rieger M, Ferrari S, Kremer Hovinga JA, Konetschny C, Herzog
A, Koller L, Weber A, Remuzzi G, Dockal M, Plaimauer B,
Scheiflinger F (2006) Relation between ADAMTS13 activity and
ADAMTS13 antigen levels in healthy donors and patients with
thrombotic microangiopathies (TMA). Thromb Haemost 95(2):
212–220
39. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A,
Gerstenbauer G, Konetschny C, Zimmermann K, Scharrer I,
Peyvandi F, Galbusera M, Remuzzi G, Bohm M, Plaimauer B,
Lämmle B, Scheiflinger F (2005) ADAMTS13 autoantibodies in
patients with thrombotic microangiopathies and other immuno-
mediated diseases. Blood 106(4):1262–1267
40. Sadler JE (2005) von Willebrand factor: two sides of a coin.
J Thromb Haemost 3(8):1702–1709
41. Scheiflinger F, Knöbl P, Trattner B, Plaimauer B, Mohr G, Dockal
M, Dorner F, Rieger M (2003) Nonneutralizing IgM and IgG
antibodies to von Willebrand factor-cleaving protease (ADAMTS-
13) in a patient with thrombotic thrombocytopenic purpura. Blood
102(9):3241–3243
42. Schneppenheim R, Angerhaus D, Obser T, Scheiflinger F, Will K,
Budde U (2003) Molecular mechanisms of hereditary
ADAMTS13 deficiency. Blood 102 (Abstract)
43. Schneppenheim R, Kremer Hovinga JA, Becker T, Budde U,
Karpman D, Brockhaus W, Hrachovinova I, Korczowski B, Oyen
F, Rittich S, von Rosen J, Tjonnfjord GE, Pimanda JE, Wienker
TF, Lämmle B (2006) A common origin of the 4143insA
ADAMTS13 mutation. Thromb Haemost 96(1):3–6
44. Shang D, Zheng XW, Niiya M, Zheng XL (2006) Apical sorting
of ADAMTS13 in vascular endothelial cells and Madin-Darby
canine kidney cells depends on the CUB domains and their
association with lipid rafts. Blood 108(7):2207–2215
45. Shelat SG,Smith P,AiJ,ZhengXL(2006) Inhibitoryautoantibodies
against ADAMTS-13 in patients with thrombotic thrombocytopenic
purpurabindADAMTS-13proteaseandmayaccelerateitsclearance
in vivo. J Thromb Haemost 4(8):1707–1717
46. Soejima K, Nakamura H, Hirashima M, Morikawa W, Nozaki C,
Nakagaki T (2006) Analysis on the molecular species and
concentration of circulating ADAMTS13 in blood. J Biochem
(Tokyo) 139(1):147–154
47. Ståhl AL, Svensson M, Mörgelin M, Svanborg C, Tarr PI,
Mooney JC, Watkins SL, Johnson R, Karpman D (2006)
Lipopolysaccharide from enterohemorrhagic Escherichia coli
binds to platelets through TLR4 and CD62 and is detected on
circulating platelets in patients with hemolytic uremic syndrome.
Blood 108(1):167–176
48. Studt JD, Bohm M, Budde U, Girma JP, Varadi K, Lämmle B
(2003) Measurement of von Willebrand factor-cleaving protease
(ADAMTS-13) activity in plasma: a multicenter comparison of
different assay methods. J Thromb Haemost 1(9):1882–1887
49. Tripodi A, Chantarangkul V, Bohm M, Budde U, Dong J-F,
Friedman KD, Galbusera M, Girma JP, Moake J, Rick ME,
Studt JD, Turecek PL, Mannucci PM (2004) Measurement of
von Willebrand factor cleaving protease (ADAMTS-13): results
of an international collaborative study involving 11 methods
testing the same set of coded plasmas. J Thromb Haemost 2(9):
1601–1609
50. Tsai H-M (1996) Physiologic cleavage of von Willebrand factor
by a plasma protease is dependent on its conformation and
requires calcium ion. Blood 87(10):4235–4244
51. Tsai H-M, Chandler WL, Sarode R, Hoffman R, Jelacic S, Habeeb
RL, Watkins SL, Wong CS, Williams GD, Tarr PI (2001) von
256 Eur J Pediatr (2007) 166:249–257Willebrand factor and von Willebrand factor-cleaving metal-
loprotease activity in Escherichia coli O157:H7-associated hemo-
lytic uremic syndrome. Pediatr Res 49(5):653–659
52. Tsai H-M, Lian EC (1998) Antibodies to von Willebrand factor-
cleaving protease in acute thrombotic thrombocytopenic purpura.
N Engl J Med 339(22):1585–1594
53. Tsai H-M, Nagel RL, Hatcher VB, Sussman II (1989) Multimeric
composition of endothelial cell-derived von Willebrand factor.
Blood 73(8):2074–2076
54. Tsai H-M, Raoufi M, Zhou W, Guinto E, Grafos N, Ranzurmal S,
Greenfield RS, Rand JH (2006) ADAMTS13-binding IgG are
present in patients with thrombotic thrombocytopenic purpura.
Thromb Haemost 95(5):886–892
55. Tsai H-M, Sussman II, Nagel RL (1994) Shear stress enhances
the proteolysis of von Willebrand factor in normal plasma. Blood
83(8):2171–2179
56. Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama
T, Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H,
Fujimura Y (2005) Localization of ADAMTS13 to the stellate
cells of human liver. Blood 106(3):922–924
57. Váradi K, Schreiner J, Plaimauer B, Rieger M, Scheiflinger F,
Knöbl P, Turecek PL, Schwarz HP (2003) ADAMTS13 autoan-
tibody detection by quantitative immunoblotting. Blood 102(5):
1932–1933
58. Vaziri-Sani F, Holmberg L, Sjöholm AG, Kristoffersson AC,
Manea M, Fremeaux-Bacchi V, Fehrman-Ekholm I, Raafat R,
Karpman D (2006) Phenotypic expression of factor H mutations
in patients with atypical hemolytic uremic syndrome. Kidney Int
69(6):981–988
59. Whitelock JL, Nolasco L, Bernardo A, Moake J, Dong J-F, Cruz
MA (2004) ADAMTS-13 activity in plasma is rapidly measured
by a new ELISA method that uses recombinant VWF-A2 domain
as substrate. J Thromb Haemost 2(3):485–491
60. Wu JJ, Fujikawa K, Lian EC, McMullen BA, Kulman JD, Chung
DW (2006) A rapid enzyme-linked assay for ADAMTS-13.
J Thromb Haemost 4(1):129–136
61. Zhou W, Tsai H-M (2004) An enzyme immunoassay of
ADAMTS13 distinguishes patients with thrombotic thrombocy-
topenic purpura from normal individuals and carriers of
ADAMTS13 mutations. Thromb Haemost 91(4):806–811
Eur J Pediatr (2007) 166:249–257 257